Clinical Study
Reduction in Endometrioma Size with Three Months of Aromatase Inhibition and Progestin Add-Back
Table 1
Baseline demographics of study population.
| | Mean ± SD | Range |
| Age/years | 32.4 ± 7.6 | 23–41 | BMI/kg/m2 | 20.6 ± 2.3 | 16.7–23.2 | Number of previous providers consulted for pain | 2.3 ± 1.3 | 1–4 | Time since onset of symptoms/years | 8.2 ± 8.4 | 1–22 | Mean baseline endometrioma diameter/cm | 4.6 ± 1.6 | 1.7–7.4 | Mean baseline endometrioma volume/cm3 | 60.1 ± 58.7 | 2.6–212.2 |
|
|